Primary Job Title Co-Founder, Vice President, CSO & SVP of Research Primary Organization 
GlycoMimetics
Location Washington, District of Columbia, United States Regions Washington DC Metro Area, Southern US Gender Male
LinkedIn View on LinkedIn
John Magnani is an expert in glycobiology having identified and characterized many carbohydrate tumor antigens, such as CA19-9, and developed fundamental technology for the identification of functional carbohydrate epitopes. Dr. Magnani is the discoverer of Sialyl Lewisa and its functions. He was the first to identify the binding domain to the
selectins common to both Sialyl Lewisa and Sialyl Lewisx and used this information to develop potent selectin antagonists.
Prior to co-founding GlycoMimetics, Dr. Magnani founded and led GlycoTech Corporation as its President and CEO. Previously, he helped co-found the U.S. subsidiary of BioCarb and became its Vice President of Research.
Dr. Magnani received his Ph.D. from Princeton University and then joined the Laboratory of Biological Pharmacology of the National Institute of Arthritis, Diabetes and Digestive and Kidney Diseases, (NIADDK) of the National Institutes of Health. He remained at the NIH for ten years, finally serving as a tenured Research Chemist.
